Xstrahl to Feature Dual Modality Treatment Solution for Dermatologists at ASMS 2024

June 10, 2024

Xstrahl to Feature Dual Modality Treatment Solution for Dermatologists at ASMS 2024
Radiant™ Aura is a painless, non-surgical office-based radiation therapy treatment option for patients with non-melanoma skin cancers and keloid scarring


Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the 2024 American Society for Mohs Surgery (ASMS) Annual Meeting at The Loews Sapphire Falls in Orlando, FL from June 20-23, 2024.

“We are pleased to feature Radiant Aura at this year’s ASMS meeting. Radiant Aura is a painless non-surgical skin cancer treatment alternative available to support the delivery of office-based radiation therapy for patients with NMSC when surgery is not possible, contraindicated, or simply not preferred due to cosmetic concerns,” said Adrian Treverton, CEO of Xstrahl.

Radiant Aura is a low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring. It is the only dual modality system that offers both non-invasive electronic brachytherapy (eBt) and superficial radiation therapy (SRT) for NMSC and keloid scarring.

To be placed on the VIP List for private events at the conference, please email kellywithers@xstrahl.com.

Visit Xstrahl at ASMS 2024 at The Loews Sapphire Falls from June 20-23, 2024.

# # #

For further information, please contact:
Kelly Withers, National Sales Director
Cell: 602-509-4990 or e-mail: kellywithers@xstrahl.com

To learn more about Radiant Aura, visit https://xstrahl.com/asms-2024/
To learn more about all Xstrahl clinical and research systems, visit www.xstrahl.com

About Xstrahl
Xstrahl is a medical technology company that designs radiation delivery devices to support clinical teams and cancer researchers. For more than 25 years, Xstrahl has been shaping the development of superficial and orthovoltage radiation therapy and advancing preclinical radiation research. Xstrahl systems are in operation at more than 700 treatment and research facilities worldwide.




Contact Us

Find out more about how Xstrahl will work tirelessly for you

Explore Related Posts